Editorial Comment from Dr Teishima and Dr Matsubara to Prognostic impact of the pretreatment aspartate transaminase/alanine transaminase ratio in patients treated with first-line systemic tyrosine kinase inhibitor therapy for metastatic renal cell carcinoma

Int J Urol. 2018 Jun;25(6):603-604. doi: 10.1111/iju.13592. Epub 2018 May 13.

Authors

Jun Teishima¹, Akio Matsubara¹

Affiliation

¹ Department of Urology, Graduate School of Biomedical and Health Science, Hiroshima University, Hiroshima, Japan.

PMID: 29756359
DOI: 10.1111/iju.13592

No abstract available

Publication types

Editorial
Comment

MeSH terms

Alanine Transaminase
Aspartate Aminotransferases*
Carcinoma, Renal Cell*
Humans
Kidney Neoplasms
Prognosis
Protein-Tyrosine Kinases

Substances

Aspartate Aminotransferases
Alanine Transaminase
Protein-Tyrosine Kinases